{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:14:00Z","timestamp":1785417240110,"version":"3.56.0"},"reference-count":49,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Center, Poland","doi-asserted-by":"publisher","award":["2016\/21\/D\/NZ7\/01573"],"award-info":[{"award-number":["2016\/21\/D\/NZ7\/01573"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Center, Poland","doi-asserted-by":"publisher","award":["N42\/DBS\/000311"],"award-info":[{"award-number":["N42\/DBS\/000311"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Center, Poland","doi-asserted-by":"publisher","award":["N42\/DBS\/000209"],"award-info":[{"award-number":["N42\/DBS\/000209"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Funds for Statutory Activity of Jagiellonian University Medical College","award":["2016\/21\/D\/NZ7\/01573"],"award-info":[{"award-number":["2016\/21\/D\/NZ7\/01573"]}]},{"name":"Funds for Statutory Activity of Jagiellonian University Medical College","award":["N42\/DBS\/000311"],"award-info":[{"award-number":["N42\/DBS\/000311"]}]},{"name":"Funds for Statutory Activity of Jagiellonian University Medical College","award":["N42\/DBS\/000209"],"award-info":[{"award-number":["N42\/DBS\/000209"]}]},{"name":"Jagiellonian University","award":["2016\/21\/D\/NZ7\/01573"],"award-info":[{"award-number":["2016\/21\/D\/NZ7\/01573"]}]},{"name":"Jagiellonian University","award":["N42\/DBS\/000311"],"award-info":[{"award-number":["N42\/DBS\/000311"]}]},{"name":"Jagiellonian University","award":["N42\/DBS\/000209"],"award-info":[{"award-number":["N42\/DBS\/000209"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>This study aimed to extend the body of preclinical research on prototype dual-acting compounds combining the pharmacophores relevant for inhibiting cyclic nucleotide phosphodiesterase 10 (PDE10A) and serotonin 5-HT1A\/5-HT7 receptor (5-HT1AR\/5-HT7R) activity into a single chemical entity (compounds PQA-AZ4 and PQA-AZ6). After i.v. administration of PQA-AZ4 and PQA-AZ6 to rats, the brain to plasma ratio was 0.9 and 8.60, respectively. After i.g. administration, the brain to plasma ratio was 5.7 and 5.3, respectively. An antidepressant-like effect was observed for PQA-AZ6 in the forced swim test, after chronic 21-day treatment via i.p. administration with 1 mg\/kg\/day. Both compounds revealed an increased level of brain-derived neurotrophic factor (Bdnf) mRNA in the hippocampus and prefrontal cortex. Moreover, PQA-AZ4 and PQA-AZ6 completely reversed (+)-MK801-induced memory disturbances comparable with the potent PDE10 inhibitor, compound PQ-10. In the safety profile that included measurements of plasma glucose, triglyceride, and total cholesterol concentration, liver enzyme activity, the total antioxidant activity of serum, together with weight gain, compounds exhibited no significant activity. However, the studied compounds had different effects on human normal fibroblast cells as revealed in in vitro assay. The pharmacokinetic and biochemical results support the notion that these novel dual-acting compounds might offer a promising therapeutic tool in CNS-related disorders.<\/jats:p>","DOI":"10.3390\/ijms231911452","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T22:53:19Z","timestamp":1664405599000},"page":"11452","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Antidepressant-like Activity, Effects on Recognition Memory Deficits, Bioavailability, and Safety after Chronic Administration of New Dual-Acting Small Compounds Targeting Neuropsychiatric Symptoms in Dementia"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5388-1214","authenticated-orcid":false,"given":"Magdalena","family":"Jastrz\u0119bska-Wi\u0119sek","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3946-1192","authenticated-orcid":false,"given":"Magdalena","family":"Kota\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Screening, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Grzeszczak","sequence":"additional","affiliation":[{"name":"Department of Lipids and Liposomes, Faculty of Biotechnology, University of Wroc\u0142aw, 50-383 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7921-8007","authenticated-orcid":false,"given":"Anna","family":"Jaromin","sequence":"additional","affiliation":[{"name":"Department of Lipids and Liposomes, Faculty of Biotechnology, University of Wroc\u0142aw, 50-383 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5670-9866","authenticated-orcid":false,"given":"Maria","family":"Walczak","sequence":"additional","affiliation":[{"name":"Chair and Department of Toxicology, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Partyka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3501-8350","authenticated-orcid":false,"given":"Joanna","family":"Gdula-Argasi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Radioligands, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Smolik","sequence":"additional","affiliation":[{"name":"Chair and Department of Toxicology, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-7237","authenticated-orcid":false,"given":"Agnieszka","family":"Zag\u00f3rska","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(2007). A decade of drug-likeness. Nat. Rev. Drug Discov., 6, 853.","DOI":"10.1038\/nrd2460"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrd2275","article-title":"Determining druggability","volume":"6","author":"Owens","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fchem.2020.00176","article-title":"A Definition of \u201cMultitargeticity\u201d: Identifying Potential Multitarget and Selective Ligands Through a Vector Analysis","volume":"8","author":"Salazar","year":"2020","journal-title":"Front. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sampietro, A., P\u00e9rez-Areales, F.J., Mart\u00ednez, P., Arce, E.M., Galdeano, C., and Mu\u00f1oz-Torrero, D. (2022). Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis. Pharmaceuticals, 15.","DOI":"10.3390\/ph15050545"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1021\/acs.jmedchem.1c00048","article-title":"Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer\u2019s Disease","volume":"64","author":"Rossi","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rankovic, Z., Hargreaves, R., and Bingham, M. (2012). CHAPTER 19: Multi-target Drug Discovery for Psychiatric Disorders. Drug Discovery for Psychiatric, RSC Publishing.","DOI":"10.1039\/9781849734943"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kondej, M., St\u0119pnicki, P., and Kaczor, A.A. (2018). Multi-Target Approach for Drug Discovery against Schizophrenia. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103105"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/DDDT.S257494","article-title":"Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases","volume":"14","author":"Makhoba","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"114218","DOI":"10.1016\/j.ejmech.2022.114218","article-title":"Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia","volume":"233","author":"Bucki","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_11","unstructured":"(2022, April 18). ICH M3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/ich-m3-r2-non-clinical-safety-studies-conduct-human-clinical-trials-pharmaceuticals."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107937","DOI":"10.1016\/j.pharmthera.2021.107937","article-title":"Translating biased agonists from molecules to medications: Serotonin 5-HT 1A receptor functional selectivity for CNS disorders","volume":"229","author":"Kleven","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/1389450119666180808105056","article-title":"Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research","volume":"20","author":"Jankowska","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.2174\/0929867325666180309110629","article-title":"Phosphodiesterase 10 Inhibitors\u2014Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery","volume":"25","author":"Zagorska","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ardp.201600260","article-title":"Aminoalkyl Derivatives of 8-Alkoxypurine-2,6-diones: Multifunctional 5-HT1A\/5-HT7 Receptor Ligands and PDE Inhibitors with Antidepressant Activity","volume":"349","author":"Bucki","year":"2016","journal-title":"Arch. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/14756366.2018.1437155","article-title":"Synthesis and biological evaluation of N-arylpiperazine derivatives of 4,4-dimethylisoquinoline-1,3(2H,4H)-dione as potential antiplatelet agents","volume":"33","author":"Marcinkowska","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Partyka, A., Zag\u00f3rska, A., Kota\u0144ska, M., Walczak, M., Jastrz\u0119bska-Wi\u0119sek, M., Knutelska, J., Bednarski, M., G\u0142uch-Lutwin, M., Mordyl, B., and Janiszewska, P. (2020). Antidepressant-like activity and safety profile evaluation of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione derivatives as 5-HT1A receptor partial agonists. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237196"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/mp.2017.36","article-title":"Identifying fast-onset antidepressants using rodent models","volume":"22","author":"Ramaker","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.npp.1301574","article-title":"Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms","volume":"33","author":"Pittenger","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.biopsych.2006.02.013","article-title":"A neurotrophic model for stress-related mood disorders","volume":"59","author":"Duman","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1523\/JNEUROSCI.16-07-02365.1996","article-title":"Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus","volume":"16","author":"Nibuya","year":"1996","journal-title":"J. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1523\/JNEUROSCI.15-11-07539.1995","article-title":"Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments","volume":"15","author":"Nibuya","year":"1995","journal-title":"J. Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav. Brain Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bbr.2011.01.052","article-title":"Effects of the cognition impairer MK-801 on learning and memory in mice and rats","volume":"220","author":"Rutten","year":"2011","journal-title":"Behav. Brain Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/schbul\/sbr133","article-title":"Is the Acute NMDA Receptor Hypofunction a Valid Model of Schizophrenia?","volume":"38","author":"Adell","year":"2012","journal-title":"Schizophr. Bull."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/sj.npp.1300761","article-title":"Cholinesterase Inhibitors Ameliorate Behavioral Deficits Induced by MK-801 in Mice","volume":"30","author":"Csernansky","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1124\/jpet.106.118976","article-title":"The Novel 7 Nicotinic Acetylcholine Receptor Agonist N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide Improves Working and Recognition Memory in Rodents","volume":"321","author":"Boess","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.neuropharm.2004.07.040","article-title":"Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance","volume":"47","author":"Boess","year":"2004","journal-title":"Neuropharmacology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2012.08.019","article-title":"Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801","volume":"236","author":"Reneerkens","year":"2013","journal-title":"Behav. Brain Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7104","DOI":"10.1073\/pnas.83.18.7104","article-title":"The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist","volume":"83","author":"Wong","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0165-0173(94)00014-G","article-title":"The N-methyl-d-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias","volume":"20","author":"Ellison","year":"1995","journal-title":"Brain Res. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.neubiorev.2008.03.012","article-title":"Models of schizophrenia in humans and animals based on inhibition of NMDA receptors","volume":"32","year":"2008","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","article-title":"Side effects of atypical antipsychotics: A brief overview","volume":"7","author":"Gaebel","year":"2008","journal-title":"World Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/13543776.2020.1709444","article-title":"Phosphodiesterase 10 (PDE10) inhibitors: An updated patent review (2014-present)","volume":"30","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1939-165X.2005.tb00041.x","article-title":"Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies","volume":"34","author":"Boone","year":"2005","journal-title":"Vet. Clin. Pathol."},{"key":"ref_37","unstructured":"(2022, April 18). Non-Clinical Evaluation of Drug-Induced Liver Injury (DILI)|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/non-clinical-evaluation-drug-induced-liver-injury-dili."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Aulbach, A.D., and Amuzie, C.J. (2017). Biomarkers in Nonclinical Drug Development, Elsevier Inc.. [2nd ed.].","DOI":"10.1016\/B978-0-12-803620-4.00017-7"},{"key":"ref_39","unstructured":"ISO (2022, April 18). ISO 10993-5:2009\u2014Biological Evaluation of Medical Devices\u2014Part 5: Tests for In Vitro Cytotoxicity. Available online: https:\/\/www.iso.org\/standard\/36406.html."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1021\/jm901713n","article-title":"Identification of 4,5-dihydro-1 H -pyrazolo[4,3- h ]quinazoline Derivatives as a new class of orally and selective polo-like kinase 1 inhibitors","volume":"53","author":"Beria","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-2999(78)90414-4","article-title":"\u201cBehavioural despair\u201d in rats and mice: Strain differences and the effects of imipramine","volume":"51","author":"Porsolt","year":"1978","journal-title":"Eur. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ejmech.2018.01.002","article-title":"Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects","volume":"145","author":"Zajdel","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sudo\u0142, S., Cios, A., Jastrz\u0119bska-wi\u0119sek, M., Honkisz-orzechowska, E., Mordyl, B., Wilczy\u0144ska-zawal, N., Sata\u0142a, G., Kucwaj-brysz, K., Partyka, A., and Latacz, G. (2021). The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910773"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s11011-015-9736-3","article-title":"Idalopirdine\u2014A small molecule antagonist of 5-HT6 with therapeutic potential against obesity","volume":"30","author":"Dudek","year":"2015","journal-title":"Metab. Brain Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s11011-016-9840-z","article-title":"H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice","volume":"31","author":"Dudek","year":"2016","journal-title":"Metab. Brain Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/abio.1996.0292","article-title":"The ferric reducing ability of plasma (FRAP) as a measure of \u201cantioxidant power\u201d: The FRAP assay","volume":"239","author":"Benzie","year":"1996","journal-title":"Anal. Biochem."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Filipczak, N., Jaromin, A., Piwoni, A., Mahmud, M., Sarisozen, C., Torchilin, V., and Gubernator, J. (2019). A Triple Co-Delivery Liposomal Carrier That Enhances Apoptosis via an Intrinsic Pathway in Melanoma Cells. Cancers, 11.","DOI":"10.3390\/cancers11121982"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1039\/C9DT03464A","article-title":"Nanoencapsulation of a ruthenium(II) complex with triazolopyrimidine in liposomes as a tool for improving its anticancer activity against melanoma cell lines","volume":"49","author":"Fandzloch","year":"2020","journal-title":"Dalt. Trans."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11452\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:41:09Z","timestamp":1760143269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":49,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijms231911452"],"URL":"https:\/\/doi.org\/10.3390\/ijms231911452","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}